by DONALD E. FRANCKE ADVERSE DRUG REACTIONS IN PERSPECTIVE THERE ARE SEVERAL REASONS why estimates of deaths due to adverse drug reactions are both inaccurate and misleading when based on extrapolations of their apparent prevalence on acute medical teaching services to the total number of hospital admissions in the United States. During recent hearings of the Senate Health Subcommittee on the "Kennedy Drug Bill" an unsubstantiated estimate was given of 30,000 deaths due to drug therapy each year in the United States. Subsequently, this number was inflated to 140,000 deaths per year, based on misleading extrapolations from two recent surveys on acute medical services. The fallacies of these extrapolations have been discussed by Dr. Jan Koch-Weser, eminent clinical pharmacologist at the Massachusetts General Hospital 1 and by Dr. Sheldon G. Gilgore, President of Pfizer Pharmaceuticals. 2 In discussing the inaccuracies of these extrapolations, they make the following points.
One of the two recent studies whose results were extrapolated to all hospitals in the United States was that conducted in 1971 by the Boston Collaborative Drug Surveillance Program which reported that for 27 (0.44 percent) of 6199 consecutively monitored medical patients in eight teaching hospitals, an adverse drug reaction was judged to be the cause of death or the most important factor in the patients' death. These figures in the hands of the extrapola*:ors becomes an estimated 140,000 deaths nationwide. A second study conducted on the acute medical service of the University of Florida Hospital found that 177 (2.9 percent) of 6063 patients were admitted because of drug-induced illness and that eleven of these died while in the hospital. When extrapolated to all hospital beds, these eleven deaths become an estimated 60,000 deaths nationwide. Of the 38 drugrelated fatalities which occurred in these two studies, eleven were in patients with cancer and almost all were in patients with serious diseases. In the Boston study, 24 of the 27 patients were undergoing treatment for lifethreatening diseases such as congestive heart failure, cirrhosis of the liver, cancer, and severe obstructive lung disease. In the Florida study, seven of the eleven deaths attributed to adverse drug reactions occurred during treatment for similar life-threatening underlying illness.
Some of the reasons that projections covering all hospital admissions cannot be made from these findings include:
1. Almost all patients admitted to hospitals because of adverse drug reactions are placed on acute medical services; it is inappropriate to extrapolate findings from these units to the entire hospital universe. The incidence of adverse drug reactions is six to ten times greater on medical wards than it is on the other wards of the hospital such as surgical, pediatrics, neurology, etc.
2. A large percentage of patients with life-threatening drug reactions go to teaching hospitals and it is not appropriate to extrapolate the findings from these hospitals to· the total hospital universe.
3. Acute medical services in teaching hospitals is the place where one finds multiple-drug therapy, often prolonged, and where the most dangerous drugs are most often used in seriously ill patients. When life-threatening diseases are treated with potent drugs, there are bound to be a certain number of untoward effects, including fatalities.
Interestingly, in the Boston study about one-third of all deaths attributed to drugs occurred following the administration of potassium chloride, physiologic saline or dextrose in water -substances usually not considered intrinsically hazardous.
These inflated estimates of drug-related deaths were given before the Senate Health Subcommittee with the implication that they might not have occurred were it not for the promotional practices of the pharmaceutical industry. Not only were statistically invalid methods used to extrapolate an extremely small non-representative sample to a national hospital population, but the implication that the promotional practices of the pharmaceutical industry were responsible is not borne out by an examination of the drugs producing the adverse reactions. About 75 percent of the drugs implicated are not promoted to any great extent by the pharmaceutical industry.
It is most unfortunate when inaccurate and grossly misleading information related to the incidence of adverse drug reactions is given before a senate committee and reported to the public via the daily press. Such reports incite the public and make it unduly apprehensive about the risk of drug therapy which is usually both life-saving and life-prolonging.
The development and use of more and more highly potent drugs during the past couple of decades undoubtedly have produced untoward effects and even death in a certain number of patients. But in most cases the benefit-to-risk ratio of drugs is relatively high.
Encouraging the safe and appropriate use of drugs in patients is the objective of several members of the healthcare team. Adverse drug reactions in patients is a serious problem, but they should be kept in proper perspective. 
